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Abstract
Background: Non-human primates (NHP) are now being considered as models for investigating human metabolic diseases
including diabetes. Analyses of cholesterol and triglycerides in plasma derived from NHPs can easily be achieved using
methods employed in humans. Information pertaining to other lipid species in monkey plasma, however, is lacking and
requires comprehensive experimental analysis.
Methodologies/Principal Findings: We examined the plasma lipidome from 16 cynomolgus monkey, Macaca fascicularis,
using liquid chromatography coupled with mass spectrometry (LC/MS). We established novel analytical approaches, which
are based on a simple gradient elution, to quantify polar lipids in plasma including (i) glycerophospholipids
(phosphatidylcholine, PC; phosphatidylethanolamine, PE; phosphatidylinositol, PI; phosphatidylglycerol, PG; phosphatidyl-
serine, PS; phosphatidic acid, PA); (ii) sphingolipids (sphingomyelin, SM; ceramide, Cer; Glucocyl-ceramide, GluCer;
ganglioside mannoside 3, GM3). Lipidomic analysis had revealed that the plasma of human and cynomolgus monkey were
of similar compositions, with PC, SM, PE, LPC and PI constituting the major polar lipid species present. Human plasma
contained significantly higher levels of plasmalogen PE species (p,0.005) and plasmalogen PC species (p,0.0005), while
cynomolgus monkey had higher levels of polyunsaturated fatty acyls (PUFA) in PC, PE, PS and PI. Notably, cynomolgus
monkey had significantly lower levels of glycosphingolipids, including GluCer (p,0.0005) and GM3 (p,0.0005), but higher
level of Cer (p,0.0005) in plasma than human. We next investigated the biochemical alterations in blood lipids of 8
naturally occurring diabetic cynomolgus monkeys when compared with 8 healthy controls.
Conclusions: For the first time, we demonstrated that the plasma of human and cynomolgus monkey were of similar
compositions, but contained different mol distribution of individual molecular species. Diabetic monkeys exhibited
decreased levels of sphingolipids, which are microdomain-associated lipids and are thought to be associated with insulin
sensitivity. Significant increases in PG species, which are precursors for cardiolipin biosynthesis in mitochondria, were found
in fasted diabetic monkeys (n=8).
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Introduction
Diabetes is a worldwide public health challenge. WHO
estimates that more than 220 million people worldwide have
diabetes and 1.1 million people died from the disease in 2005. Its
incidence is increasing rapidly due to aging, urbanization, and
increasing prevalence of obesity and sedentary lifestyle [1].
Furthermore, it is estimated that over 30% of diabetic population
remain undiagnosed [2]. On another note, despite the availability
of many anti-diabetic agents, current treatment goals are often
unmet and are often constrained by weight gain, tolerability, safety
and gastrointestinal intolerance The various limitations aforemen-
tioned demand an immediate and ideal therapeutic intervention
for the disease. The development of a reliable diagnostic test would
therefore not only be highly beneficial for clinical purposes, but
also for the testing of response to new drug in animal models.
Obesity is the single most important contributor to insulin
resistance [3]. Elevated levels of plasma lipids had been shown to
cause changes in cellular lipid metabolism that would lead to
intracellular lipid accumulation, compromising other organ
functions as a result. Increasing emphasis has been placed on
the measurement of triglycerides, non-esterified fatty acids
(NEFAs) and cholesterol levels in the plasma as well as in specific
tissues susceptible to lipid accumulation that would affect normal
physiologic function as a result [4]. Recently, inhibition of
sphingolipid synthesis was shown to increase insulin sensitivity in
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19731cultured cells and rodent models [5,6,7,8,9,10,11]. Mice lacking
the GM3 synthase (GMS) have elevated insulin sensitivity [12].
Moreover, patients with Type I Gaucher disease, a lysosomal
storage disease caused by a failure to degrade glucosylated
ceramides, are insulin-resistant [13]. The ‘‘membrane microdo-
main ortho-signalling therapy’’ represents an emerging concept
that opens a new therapeutic window for the treatment of
metabolic disorders. It proposes that metabolic disorders can arise
as a result of disorganizations in membrane microdomains due to
the aberrant expression of gangliosides [14]. These findings
cumulatively suggest that quantitative changes in sphingolipids
can be potentially relevant modulators of insulin action.
Non-human primates (NHPs) are more closely related to human
compared to rodents. As such, they are currently being considered
as the primary model for evaluation of diabetic drugs [15,16,17].
Nevertheless, information on the lipid profiles of monkey plasma
has not been previously reported, probably due to a lack in the
state-of-the-art techniques for lipid analysis and the lower
accessibility of monkeys to academic research. A quantitative
analysis of monkey plasma lipids could therefore provide
important biological insights into the understanding of metabolic
syndrome. Technological advancements, most notably in liquid
chromatography and mass spectrometry, allow sensitive and
highly selective analysis of lipids with diverse chemical composition
and in complex mixtures [18,19]. In particular, the introduction of
tandem MS has spurred the development of various quantitative
approaches, such as precursor ion scanning, neutral loss scanning,
and MRM scanning for the targeted lipidomic analysis of complex
samples[20,21,22]. Therefore, the development of lipid biomark-
ers for diabetes using mass spectrometry would facilitate the
diagnostic process and enable more effective treatment monitoring
of the disease. To our knowledge, this is the first study carried out
to characterize monkey plasma lipids in parallel with human
plasma lipids. This study also aims to investigate the potential lipid
biomarker(s) for diabetes using monkey as a scale-down model for
potential applications in human drug evaluation.
Results
Characterization of monkey plasma lipids using precursor ion
scans (PreIS) indicated that the lipid species in monkey and human
plasma are similar. This validated our approach in using similar
analytical methods for the analyses of plasma samples from the two
species. Here, we used a simple LC gradient elution to separate
various classes of polar lipids (Figure 1A), in the plasma before
introduction into mass spectrometer for quantification. In negative
ESI mode, PG, PE, PI, PS, PA and GM3 species eluted out of
column in the stated order with good separation. In positive ESI
mode, Cer species flowed out of the column first, subsequently
followed by GluCers, PCs and SMs. The various MRM transitions
for all lipid species were monitored and their intensities measured
[23]. The quantity of individual species was calculated by
comparing its measured intensity with that of spiked internal
standards. Primarily, we focused our analysis on phospholipids and
sphingolipids, in particular for glycosphingolipids such as gangli-
oside GM3 and GluCer species. For the first time, we are able to
quantify individual ganglioside GM3 species in both human and
monkey using synthetic C17-ganglioside GM3 standard and
specific MRM transitions.
Comparison of plasma lipid profiles between monkey
and human
Analyses of total lipid fraction of individual classes of lipids were
shown in Figure 1B. Similar to the trend observed in human, PC
was the most abundant phospholipid species in monkey plasma,
followed by SM, LPC, PE and PI (Figure 1B). PC was significantly
higher in the plasma of human than monkey, while other
phospholipid species including PI and PE displayed the opposite
trend (Figure 1B). Among sphingolipid species measured in human
and monkey plasma, GM3, Cer and GluCer were found to be
significantly different in quantities (Figure 1B). The levels of GM3
and GluCer in human plasma were nearly fourfold of that in
monkey plasma; while the level of Cer in monkey plasma was
approximately double of that in human plasma. However, the
level of SM was not found to be significantly different between the
two species (Figure 1B, insert).
The levels of individual lipid species in human and monkey
plasma were quantified and the differences were illustrated by the
heat plots in Figure 2. Although human and monkey plasma
contained the same lipid species, individual lipid species was found
in different quantities. For instance, the levels of plasmalogen PE
species (p,0.005) and plasmalogen PC species (p,0.0005) were
significantly higher in human plasma than in monkey plasma
(Figure 3), while the levels of polyunsaturated fatty acyls (PUFA),
including PC40:6, PC40:5, PC38:6, PE40:6, PE40:5, PE38:6,
PE38:5, PE38:4, were significantly higher in the plasma of monkey
than that in human (Figure 2A, 2B). Ganglioside GM3, Cer and
GluCer also showed dissimilar trend in the distribution of each
lipid species (Figure 2H, 2I, 2J).
TAG profiles in human and monkey plasma demonstrated that
monkey plasma contained higher levels of TAG 52:5, 52:4, 56:8,
56:7, 56:6, 58:10, 58:9, 58:8, 58:7 and 58:6 (Figure S1).
Changes in plasma lipidome of diabetic monkeys under
fed and fasting conditions
Diabetic monkeys demonstrated significantly higher levels of
insulin, glucose and alanine transaminase (ALT) as well as slightly
elevated levels of aspartate transaminase (AST) (Figure 4A–D).
The differences in the levels of insulin and glucose under fasting
condition were of greater significance than those acquired under
normal chow-feeding condition (Figure 4A–B). Dramatic increases
in plasma triacylglyceride levels in diabetic monkeys were also
observed (Figure 4E), while there were no significant changes for
the levels of cholesterol, HDL-cholesterol and LDL-cholesterol
(Figure 4F–H).
Crude extracts of plasma from normal and diabetic monkeys
under fasting and fed conditions were examined by LCMS to
quantitatively assess the differences in the levels of phospholipids
and sphingolipids (Figure 5, 6, 7, Figure S2). The results showed
that the supply of food did not cause considerable changes in
plasma glycerophospholipids of normal or diabetic monkeys
(Figure 5). We also compared the lipid profiles of diabetic
monkeys at different ages; and lipidomic analysis revealed that
there was no significant correlation between the levels of both
glycerophospholipids and sphingolipids with age (12 to 20 years
old). The diabetic monkeys were further stratified into two age
groups and no appreciable changes in the quantities of the two
lipid classes aforementioned were observed (Figure S3A, S3B). The
maximum lifespan and age at sexual maturation of cynomolgus
monkeys are 27 years and 3 years respectively [24]. Therefore, all
monkeys (both normal controls and diabetic groups) used in the
current study are considered sexually matured adults belonging to
either the young (approximately 5 years) or middle-age categories
(approximately 16 years), indicating that age was likely not a
predominant factor for causing the observed changes in lipid levels
between the diabetic and control groups in the current
experimental design.
Plasma Lipidomics in Diabetic Monkeys
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glycerophospholipids (Figure 5A–B) except for PG, with the total
PG level being significantly higher in diabetic monkeys compared
to normal monkeys under fasting condition (Figure 5B). On the
other hand, total LPI level was significantly lower in fed diabetic
monkeys (Figure 5A).
The levels of total GM3, GluCer and SM were significantly
lower in fasting diabetic monkeys than corresponding controls
(Figure 5A, 5B). Moreover, detailed sphingolipid profiles indicated
that a majority of the individual SM, GM3 and GluCer species
followed the same general trend and were significantly decreased
in the plasma of diabetic monkeys under both fed and fasting
conditions compared to normal controls (Figure 6).
Discussion
Plasma contains distinct lipid species yet the functions of many
of these lipids remain poorly understood, particularly at the
Figure1.Majorlipidspeciesinhumanandmonkey. (A) Chemical structure of plasma lipids. (B) Comparison of total mol fraction of phospholipid
and sphingolipids species in Human (n=10) and normal, fed Monkey plasma (n=8). Insert, PG, GM3, Cer, Glucer. * p,0.05, ** p,0.005, *** p,0.0005.
doi:10.1371/journal.pone.0019731.g001
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deregulated lipid metabolism plays an important role in many
human diseases including metabolic syndrome diseases such as
diabetes [25]. While the blood cholesterol and triacylglyceride
levels of patients are diagnostic criteria regularly used by doctors
for diabetes, information on other polar lipids, in particular
sphingolipids and glycerophospholipids, is missing and gaining
increasing interest from both researchers and doctors. Thus,
monitoring the changes in various plasma polar lipids represents
an emerging field in the treatment of metabolic syndrome and can
possibly confer new perspectives in terms of disease diagnosis,
molecular mechanisms triggering the disease and evaluation of
treatment responses. Technological advancements, most notably
in mass spectrometry, allow sensitive analysis of various lipids with
diverse chemical composition. It is well-recognized now that
glycerophospholipids and sphingolipids are well-ionized by
electrospray. For instance, phosphatidylinositol (PI), phosphatidyl-
ethanolamine (PE), phosphatidylserine (PS), phosphatidylglycerol
(PG), phosphatidic acid (PA) and gangliosides are better ionized in
negative ESI mode [19]; while phosphatidylcholine (PC) ionizes
Figure 2. Heatplots of various polar lipids in normal human (n=10) and normal, fed monkey plasma (n=8) (A) PC,
phosphatidylcholine; (B) PE, phosphatidylethanolamine; (C) PI, phosphatidylinositol; (D) PA, phosphatidic acid; (E) PG,
phosphatidylglycerol; (F) PS, phosphatidylserine; (G) SM, sphingomyelin; (H), Cer, Ceramides; (I) GM3, ganglioside mannoside;
(J), Glucer, glucosylceramides. *p ,0.05, ** p,0.005, *** p,0.0005.
doi:10.1371/journal.pone.0019731.g002
Plasma Lipidomics in Diabetic Monkeys
PLoS ONE | www.plosone.org 4 May 2011 | Volume 6 | Issue 5 | e19731much more efficiently in positive ESI mode. Most sphingolipids
(Cer, GluCer and SM) can be detected in both positive and
negative ESI modes.
In this study, we successfully separated and quantified the
various polar lipids aforementioned using LCMS approaches [22];
and for the first time, we characterized and quantified the lipid
profiles of monkey plasma and compared that with the
corresponding lipid profiles in human plasma (Figure 1). In
human plasma, our results indicated that PC and SM are most
abundant polar lipids, accounting for 58% and 18% of the total
polar lipids respectively, consistent with a recent report [26].
Lipidomic analysis revealed that PC and SM were the two most
abundant polar lipids in monkey plasma as well (Figure 1B). Also,
similar to the trend observed for human plasma, other major polar
lipids, such as LPC, PE and PI, were shown to be present in
proportionately much higher levels compared to the minor lipid
species. The higher level of PUFA-containing lipid species found
in monkey plasma could be partially attributed to a difference in
diets, as monkeys are fed with a diet rich in seasonal fruits and
vegetables [27]. Higher levels of plasmalogen species found in
human plasma is likely associated with differences in the activities
of enzymes involved in the biosynthesis of plasmalogens [28].
The similar profiles for polar lipids in human and monkey
plasma might imply an analogous lipid biogenesis pathway that is
conserved between human and cynomolgus monkeys. Further-
more, in a manner akin to human type 2 diabetes mellitus
(T2DM), diabetic cynomolgus monkeys exhibited significantly
higher plasma concentrations of TAG (Figure 4E) and marginally
significant lower levels of HDL cholesterol (Figure 4F). Lipidomic
analyses of TAG levels in diabetic monkeys also produced results
consistent with that obtained using enzymatic colorimetric method
(data not shown). These findings validated our approach in using
cynomolgus monkeys as a model for the identification of potential
lipid biomarkers that can possibly be applied to the diagnosis of the
disease in humans.
For the first time, we used a specific LC-MRM approach with
C17-GM3 ganglioside as an internal standard to quantify
individual endogenous ganglioside GM3 species (Table 1), which
are of significant value to both basic research as well as clinical
investigations. For instance, decreases in ganglioside GM3 in
Gne
M712T/M712T mouse muscle was recently reported to be
potential marker for HIBM (Hereditary Inclusion Body Myopa-
thy) diseases [29]. Furthermore, fingerprint of ganglioside GM3
can be potentially important as it is possible that changes in fatty
acyl composition (saturation and length) in individual ganglioside
GM3 species will affect its interaction with insulin receptor in
membrane microdomains or the stability of the associated
microdomains per se.
Lipidomic data from this study showed that human plasma
contained significantly higher levels of GluCer and ganglioside
GM3 lipid species (Figure 1B), which are microdomain-associated
lipids. We postulate that the levels of these lipids in other organs,
such as the liver, would display a similar trend, with the level in
human being considerably higher than that in monkey. However,
this hypothesis requires further experimental verification.
Among all polar lipid species measured in this study, significant
decreases in the levels of plasma GluCer, gangliosides GM3 and
major SM species were observed in diabetic monkeys compared to
normal controls, but not in the case of free ceramide species
(Figure 6). The decrease in GluCer and ganglioside GM3 species
in diabetic monkeys might be attributed to a down-regulation of
glycosyltransferases activity, which transfers a specific sugar (e.g.
glucose) from an appropriate sugar-nucleotide (e.g. UDP-Glc) to
ceramide. This trend observed in diabetic monkeys was unex-
pected as GM3 has been reported as a negative regulator of insulin
signaling [12,30,31]. Immediate analysis of diabetic human
plasma samples needs to be carried out before considering
glycosphingolipids as a potential therapeutic target in type 2
diabetes (ongoing work). Further studies will be required to
validate the use of peripheral GluCer and gangliosides GM3
species as potential biomarkers for detecting the onset of diabetes
in humans.
Interestingly, significant increases in the levels of plasma PG in
fasting diabetic monkeys indicate that it could be potential
biomarker (Figure 5B, Figure 7). PG is the precursor of cardiolipin,
the key class of mitochondrial phospholipid that regulates
mitochondrial function and oxidative stress [32,33]. Multiple
mechanisms have recently been proposed as the potential causes of
insulin resistance and/or diabetes progression, and impaired
mitochondrial function has emerged as a promising candidate that
can possibly play a pathogenic role in the progression of diabetes
[34,35,36,37,38,39,40]. Thus, further investigation on the polar
lipid compositions including cardiolipin species in different organs
of diabetic monkeys compared to normal controls will help to
unravel these puzzles.
In addition, a decrease in the total level of LPI (Figure 5A) and
marginally significant decreases in major PI species including
PI38:4, 36:2, 36:3, 34:2 were also observed in diabetic monkeys
under fed conditions (Figure S2). It should be noted, however, that
such changes observed under fed conditions could be complicated
by dietary factor and are thus less applicable to human clinical
studies. Moreover, as similar changes were not observed under
fasting conditions, such changes were unlikely to be a predominant
result of the disease per se.
While there are no significant changes for the levels of most
classes of phospholipids, alterations in the individual levels of
certain phospholipid species were observed (Figure S1). For
instance, there are no appreciable changes in the total level of
PE in diabetic monkeys under both fed and fasted conditions when
compared with the corresponding normal controls (Figure 5A), but
the concentrations of most plasmalogen PE species such as
pPE38:6, pPE38:5, pPE38:4 and pPE36:3 were significantly lower
in diabetic monkeys under both fasting and fed conditions (Figure
S2). Similar to the trends observed in PE species, diabetic monkeys
demonstrated significantly higher levels for most diacyl PC species
Figure 3. Comparison of mol fraction of plasmalogen lipids in
both human (n=10) and normal, fed Monkey plasma (n=8).
** p,0.005, *** p,0.0005.
doi:10.1371/journal.pone.0019731.g003
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Plasmalogen refers to a specific class of phospholipids that contains
a vinyl ether moiety at the sn-1 position of the glycerol backbone,
making these lipids highly susceptible to oxidative damage as a
result. The decreased levels of plasmalogen PE could possibly be
attributed to intense lipid peroxidation induced by increased
oxidative stress in diabetic monkeys or to a decrease in its
biogenesis in the peroxisome [28].
A major drawback in the current study is the lack of age-
matched controls due to the high cost implicated and substantial
amount of logistic difficulties involved in the recruitment of
healthy monkeys for academic investigation. In addition, the two
monkey groups are also not gender-matched and have different
body weight. Nevertheless, we did not observe significant changes
for polar lipids among monkeys in the age range of 12 to 20 years,
indicating that age was likely not a predominant factor for causing
the observed changes in lipid levels in the diabetic monkeys.
Another limitation in the current study design is the relatively
small sample size (10 healthy human subjects vs 8 healthy
monkeys; and 8 healthy monkeys vs 8 diabetic monkeys,
respectively). Further studies using age-matched controls as well
as a larger cohort size is essential to verify the preliminary findings
obtained in the current study. Nevertheless, comparative lipidomic
data between human plasma and monkey plasma could serve as a
Figure 4. Biochemical analysis of plasma in diabetic monkeys (n=8 for each group). (A) Insulin; (B) Glucose; (C) Alanine transaminase
(ALT); (D) Aspartate transaminase (AST); (E) Triacylglycerides (TAG); (F) Cholesterol; (D) Low-density lipoprotein cholesterol (LDL-C); (H) High-density
lipoprotein cholesterol (HDL-C). * p,0.05, ** p,0.005.
doi:10.1371/journal.pone.0019731.g004
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ers an excellent to follow our approach to carry out related studies.
Materials and Methods
Chemicals
Chloroform and methanol were purchased from Merck (Merck
Pte. Ltd., Singapore). Ammonium hydroxide (28% in H2O) was
purchased from Sigma-Aldrich (St. Louis, MO, USA). Deionized
water was obtained from a MilliQ purification system (Millipore,
Bedford, MA, USA). PC-14:0/14:0, PE-14:0-14:0, PS-14:0/14:0,
PA-17:0/17:0, PG-14:0/14:0, d31-PI-18:1/16:0, C17-Cer, C8-
GucCer and C12-SM were obtained from Avanti Polar Lipids
(Alabaster, AL, USA). Dioctanoyl phosphatidylinositol PI-8:0/8:0
was purchased from Echelon (Echelon Biosciences, Inc., Salt Lake
City, UT, USA). C17-ganglioside GM3 was provided by Lilly.
Monkey colony, selection and animal care
Sixteen cynomolgus monkeys, which were introduced from
different regions of Southeast Asia, were selected from a colony in
Guangdong Landau Biotech Co. (Guangdong, China) (Table S1).
There is no inbreeding within this colony. Eight monkeys had
developed hyperglycemia and hyperlipidemia spontaneously and
were identified from the colony during the screening process. Eight
other monkeys were normal and used as controls.
The animal welfare and steps taken to ameliorate suffering were
in accordance with the recommendations of the Weatherall report
on the use of non-human primates in research. Upon receiving the
animals, a quarantine and acclimation period of approximately
one month was allowed before any experiments were initiated in
order to prevent the transmission of potentially contagious diseases
and for the monkeys to adapt to the lab environment. Crown
Bioscience Institutional Animal Care and Use Committee
(IACUC) approved all animals procedures used in conducting
these studies (Pri-dia-0901-010C). The monkeys were individually
housed and maintained in accordance with the guidelines
approved by the Association for Assessment and Accreditation of
Laboratory Animal Care (AAALAC). All the procedures related to
handling, care and treatment in this study were performed
according to guidelines approved by the AAALAC.
Water was available ad libitum. All monkeys were fed twice
daily with a complete, nutritionally balanced diet rich with
seasonal fruits and vegetables.
Collection of monkey plasma samples
Blood samples were collected from 8 diabetic and 8 normal
control cynomolgus monkeys under fed and fasting conditions for
Figure 5. Comparison of total lipids in plasma of normal (n=8) and diabetic (n=8) monkey groups under both fasted and fed
conditions. *p ,0.05, ** p,0.005, *** p,0.0005.
doi:10.1371/journal.pone.0019731.g005
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overnight and 4 mL of blood was collected from a peripheral vein
into an EDTA tube under ketamine (10 mg/kg IM injection)
anesthesia. Blood samples under fed conditions were collected 2
days later. The monkeys were fed with normal chow (Shanghai
shilin biotech Co., Ltd) at 8:00am following overnight fasting. Four
mL of blood was collected from a peripheral vein into an EDTA
tube at around one hour later under ketamine anesthesia.
Figure 6. Individual sphingolipid species in plasma of normal (n=8) and diabetic (n=8) monkey under fasted and fed condition: (A)
Cer, (B) SM (C), GluCer, (D) GM3. *p ,0.05, ** p,0.005, *** p,0.0005.
doi:10.1371/journal.pone.0019731.g006
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The collected plasma was divided into 4 aliquots of 500 ul each
and stored at 270uC. One aliquot was used for biochemical
analysis, and remaining aliquots were used for LC-MS analysis
of lipids.
Collection of human plasma samples
Blood samples from 10 healthy non-fasting volunteers (Table
S1) were collected in EDTA tubes at National University Hospital,
Singapore. This study was approved by the institutional review
board of National University of Singapore (04-115). All partici-
pants gave written informed consent for his study.
Measurement of blood chemistry
Plasma total cholesterol (Cho) and triacylglycerides (TG) were
measured using Cobas agents, Cholesterol-chod-pap and Triacyl-
glycerides-GPO-PAP, respectively (Roche Diagnostics, Indianap-
olis, IN) by enzymatic colorimetric method. Glucose, alanine
transaminase (ALT) and aspartate transaminase (AST) were
measured using Cobas agents, Gluco-quant Glucose/HK, alanine
transaminase acc. to IFCC with/without pyridoxal phosphate
activation and aspartate transaminase acc. to IFCC with/without
pyridoxal phosphate activation and (Roche Diagnostics), respec-
tively, in UV test. High-density lipoprotein cholesterol (HDL) and
low-density lipoprotein were measured using Cobas agents, HDL-
cholesterol, no pretreatment, and LDL-cholesterol, no pretreat-
ment, in homogeneous enzymatic colorimetric assay. Plasma
insulin was assayed with Cobas Insulin agent in sandwich method.
TC, TG, Glucose, ALT, AST, HDL and LDL were measured
using a Clinical Analyzer Model 7600 (Hitach High-Technologies,
Tokyo, Japan), and Insulin utilizing an E 170 Modules for
MODULAR ANALYTICS (Roche Professional Diagnostics,
Mannheim, Germany).
Lipid extraction
Ice-cold solvent mixture (900 ml of chloroform:methanol,
1:2v/v) was added to 100 ml of plasma sample, vortexed, and
incubated on ice in a vacuum chamber in a dark room for 1 h
with agitation. After incubation, 0.3 ml of chloroform was added
to the homogenate, followed by 0.35 ml of ice-cold water. The
homogenate was then vortexed for 30 sec and centrifuged for
2 min at 9,000 rpm. The bottom organic phase was carefully
transferred to an empty tube, and 0.5 ml of ice-cold chloroform
was added for reextraction. The two organic extracts were then
combined and dried under nitrogen. To ensure all lipids
investigated were reasonable recovered, recovery of various
lipids using in current extraction protocol were compared with a
recent reported protocol [41], and comparable recoveries were
obtained for all lipids investigated in this study.
Quantitative analysis of lipids using HPLC/MS
Individual classes of polar lipids were separated using an Agilent
1200 HPLC system before introduction into a 3200 Q-Trap mass
spectrometer (Applied Biosystems). The HPLC system contained
an Agilent 1200 binary pump, an Agilent 1200 thermo sampler,
and an Agilent 1200 column oven. HPLC conditions: Luna 3-mm
silica column (i.d. 15062.0 mm); mobile phase A (chloroform:-
methanol:ammonium hydroxide, 89.5:10:0.5), B (chloroform:-
methanol:ammonium hydroxide:water, 55:39:0.5:5.5); flow rate
300 ml/min; 5% B for 3 min, then linearly switched to 30% B in
24 min and maintained for 5 min, and then linearly changed to
70% B in 5 min and maintained for 7 min. Then, the composition
of the mobile phase was returned to the original ratio] over
5 min and maintained for 6 min before the next sample was
analyzed. Mass spectrometry was recorded under both positive
and negative ESI modes with EMS scan type, and ESI conditions
are: Turbo Spray source voltage, 5000 and 24500 volts for
positive and negative, respectively; source temperature, 300uC;
GS1: 40.00, GS2: 40.00, curtain gas: 25. PC, SM, Cer and
GluCer are acquired in the positive ESI mode, while PE, PI, PS,
PG, PA and GM3 are measured in in the negative ESI mode.
Collision energies ranged from 20 to 65 volts for various lipid
species in MS/MS scan modes. Multiple MRM transitions for
individual GPL (PG, PE, PC, PI, PS and PA) species and SPL
(SM, Cer, GluCer and GM3) were set up at different elution
stages for LC-MS analysis [22,23,42]. Multiple reaction moni-
toring transitions of individual lipid species were listed in Table 1
(Table 1). Individual lipid species were quantified by comparison
with spiked internal standards PC-14:0/14:0, PE-14:0-14:0, PS-
14:0/14:0, PA-17:0/17:0, PG-14:0/14:0, d31-PI18:1/16:0, PI-
8:0/8:0, C17-LPC, C17-LPA, C17-LPS, C17-Cer, C8-GluCer,
C12-SM and C17-ganglioside GM3. The molar fractions of
individual lipid species and each lipid class were normalization to
summation of all polar lipid species aforementioned for
comparison.
Neutral lipids were analyzed to verify data obtained using
biochemical analysis aforementioned using HPLC/ESI/MS as
described previously [43]. Briefly, triglycerides were separated
from polar lipids on an Agilent Zorbax Eclipse XDB-C18 column
(i.d. 4.66150 mm), with chloroform:methanol:0.1 M ammonium
Figure 7. Comparison of individual PG species in normal (n=8) and diabetic (n=8) monkey under fasted and fed condition.
*p ,0.05, ** p,0.005, *** p,0.0005.
doi:10.1371/journal.pone.0019731.g007
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Lipid Species MRM Transition Lipid Species MRM Transition Lipid Species MRM Transition
PC- 34:2 758R184 PE- 36p:3 724R196 PA- 32:2 643R153
PC- 34:1 760R184 PE- 36p:2 726R196 PA- 32:1 645R153
PC- 36:4p 766R184 PE- 36p:1 728R196 PA- 32:0 647R153
PC- 36:3p 768R184 PE- 36:4 738R196 PA- 34:2 671R153
PC- 36:2p 770R184 PE- 36:3 740R196 PA- 34:1 673R153
PC- 36:1p 772R184 PE- 36:2 742R196 PA- 36:2 699R153
PC- 36:0p 774R184 PE- 36:1 744R196 PA- 36:1 701R153
PC- 36:5 780R184 PE- 38p:6 746R196 PA- 38:4 723R153
PC- 36:4 782R184 PE- 38p:5 748R196 LPA- 16:1 407R153
PC- 36:3 784R184 PE- 38p:4 750R196 LPA- 16:0 409R153
PC- 36:2 786R184 PE- 38:7 760R196 LPA- 18:1 435R153
PC- 36:1 788R184 PE- 38:6 762R196 LPA- 18:0 437R153
PC- 38:4p 794R184 PE- 38:5 764R196
PC- 38:3p 796R184 PE- 38:4 766R196 GM3- 18:1/16:0 1151R290
PC- 38:2p 798R184 PE- 40p:6 774R196 GM3- 18:0/16:0 1153R290
PC- 38:6 806R184 PE- 40p:5 776R196 GM3- 18:1/18:1 1177R290
PC- 38:5 808R184 PE- 40p:4 778R196 GM3- 18:1/18:0 1179R290
PC- 38:4 810R184 PE- 40:6 790R196 GM3- 18:0/18:0 1181R290
PC- 38:3 812R184 PE- 40:5 792R196 GM3- 18:1/20:1 1205R290
PC- 40:4p 822R184 PE- 40:4 794R196 GM3- 18:1/20:0 1207R290
PC- 40:3p 824R184 PE- 42p:3 808R196 GM3- 18:0/20:0 1209R290
PC- 40:2p 826R184 PE- 42p:2 810R196 GM3- 18:1/22:1 1233R290
PC- 40:1p 828R184 PE- 42:9 812R196 GM3- 18:1/22:0 1235R290
PC- 40:7 832R184 PE- 42:8 814R196 GM3- 18:0/22:0 1237R290
PC- 40:6 834R184 PE- 42:7 816R196 GM3- 18:1/24:1 1261R290
PC- 40:5 836R184 GM3- 18:1/24:0 1263R290
LPC- 16e:0 482R184 PI- 32:1 807R241 GM3- 18:0/24:0 1265R290
LPC- 16:1 494R184 PI- 34:3 831R241
LPC- 16:0 496R184 PI- 34:2 833R241 Cer- d18:1/16:0 538R264
LPC- 18:2 520R/184 PI- 34:1 835R241 Cer- d18:1/18:0 566R264
LPC- 18:1 522R184 PI- 36:4 857R241 Cer- d18:0/18:0 568R266
LPC- 18:0 524R184 PI- 36:3 859R241 Cer- d18:1/20:0 594R264
LPC- 20:0 552R184 PI- 36:2 861R241 Cer- d18:1/22:0 622R264
PI- 36:1 863R241 Cer- d18:1/24:1 648R264
PS- 34:1 760R673 PI- 38:5 883R24 Cer- d18:1/24:0 650R264
PS- 36:2 786R699 PI- 38:4 885R241 Cer- d18:0/24:0 652R266
PS- 36:1 788R701 PI- 38:3 887R241.
PS- 38:5 808R721 PI- 40:6 909R241 SM- 18/16:0 703R184
PS- 38:4 810R723 PI- 40:5 911R241 SM- 18/18:1 729R184
PS- 38:3 812R725 PI- 40:4 913R24 SM- 18/18:0 731R184
PS- 40:7 832R745 LPI- 16:1 569R241 SM- 18/20:1 757R184
PS- 40:6 834R747 LPI- 16:0 571R241 SM- 18/20:0 759R184
PS- 40:5 836R749 LPI- 18:1 597R241 SM- 18/22:1 785R184
LPS- 16:1 494R407 LPI- 18:0 599R241 SM- 18/22:0 788R184
LPS- 16:0 496R409 SM- 18/24:1 813R184
LPS- 18:1 522R435 PG- 32:1 719R153 SM- 18/24:0 815R184
LPS- 18:0 524R437 PG- 34:2 745R153
PG- 34:1 747R153 GluCer- d18:1/16:0 700R264
PE- 32:2 686R196 PG- 36:4 769R153 GluCer- d18:1/18:0 728R264
PE- 32:1 688R196 PG- 36:3 771R153 GluCer- d18:1/20:0 756R264
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0.25 mL. min
21. Selective ion monitoring was used to record
major phospholipids, sterols and TAG species. TAGs were
calculated as relative contents to the spiked d5-TAG 48:0 internal
standard (CDN isotopes) and were further normalized to total
polar lipids.
Statistics
Comparisons of the means of various plasma lipids were
performed for human and monkey groups as well as for non-
diabetic and diabetetic monkeys. Data are expressed as means
with standard deviations as indicated by the error bars. The
differences between human and monkey groups as well as for non-
diabetic and diabetic monkeys were determined statistically using
Student’s t test, and a p-value,0.05 was considered statistically
significant. The differences in individual lipid species between
human and monkey groups, as well as between non-diabetic and
diabetic monkeys were also evaluated using False Discovery Rate
(FDR) adjustment. However, most of the q-values obtained from
FDR adjustment were smaller than or approximately close to the
corresponding p-values obtained using student t-test (Table S2,
Table S3, Table S4). Thus, only p-values obtained using student t-
test were presented in figures.
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